AR 42

Drug Profile

AR 42

Alternative Names: AR-42; NSC-D736012; OSU-HDAC42

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ohio State University Research Foundation
  • Developer Arno Therapeutics; Celgene Corporation; Ohio State University Comprehensive Cancer Center; Virginia Commonwealth University
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Deacetylase inhibitors; Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Meningioma; Neurilemmoma; Neurofibromatosis 2
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic lymphocytic leukaemia; Lymphoma; Multiple myeloma; Solid tumours
  • Phase I Renal cell carcinoma; Soft tissue sarcoma
  • Phase 0 Meningioma; Neurilemmoma
  • Preclinical Bladder cancer
  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy) in USA (PO, Capsule)
  • 03 Jul 2017 Ohio State University Comprehensive Cancer Center and Celgene suspends phase I trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA, for internal data analysis (NCT02569320)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top